MCC
MCID: MRK001
MIFTS: 65

Merkel Cell Carcinoma (MCC)

Categories: Cancer diseases, Endocrine diseases, Immune diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Merkel Cell Carcinoma

MalaCards integrated aliases for Merkel Cell Carcinoma:

Name: Merkel Cell Carcinoma 12 52 58 36 15 71
Trabecular Adenocarcinoma 12 6 71
Cutaneous Neuroendocrine Carcinoma 52 58
Carcinoma, Merkel Cell 52
Carcinoma Merkel Cell 54
Trabecular Carcinoma 12
Merkel Cell Cancer 52
Merkle Tumors 52
Mcc 58

Characteristics:

Orphanet epidemiological data:

58
cutaneous neuroendocrine carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe),1-9/100000 (Australia); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare skin diseases
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:3965
KEGG 36 H01555
NCIt 49 C4068
SNOMED-CT 67 29792007
ICD10 via Orphanet 33 C44.3 C44.6 C44.7
UMLS via Orphanet 72 C0007129
Orphanet 58 ORPHA79140
UMLS 71 C0007129 C0302182

Summaries for Merkel Cell Carcinoma

KEGG : 36 Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy that exhibits clinically aggressive features and is associated with a poor prognosis. Ultraviolet (UV) radiation may be a cause, and corresponds with the sites of these tumours, often on sun-exposed skin, mostly (94%) in the White population. UV light may exert local immunomodulating action as it decreases amount of epidermal T cells and Langerhans cells, inducing hapten tolerance. Additionally, UV- specific mutations in TP53 and Harvey (Ha)-RAS genes are present in some MCC cell lines. Recently, the polyomavirus group has been linked with MCC. The MCC polyomavirus (MCPyV) has been isolated from MCC tissue and thought to be present in up to 80% of MCC. Tumorigenesis likely is caused by a number of sequential steps from viral integration into host DNA, mutagenic events, and specific immune responses.

MalaCards based summary : Merkel Cell Carcinoma, also known as trabecular adenocarcinoma, is related to skin benign neoplasm and eyelid carcinoma. An important gene associated with Merkel Cell Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Neuroscience and NF-kappaB Signaling. The drugs Bleomycin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are merkel cell skin cancer and cutaneous photosensitivity

NIH Rare Diseases : 52 Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer . It usually develops as a single, painless, bump on sun-exposed skin. The bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. It may spread quickly to surrounding tissues , nearby lymph nodes , or more distant parts of the body. Factors associated with developing MCC include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the Merkel cell polyomavirus. This virus has been detected in about 80% of people with MCC. Treatment may include surgery, radiation therapy , and/or chemotherapy . Treatment options and prognosis depend on the location(s) and size of the cancer , whether it has just been diagnosed or has come back (recurred), and how deeply it has grown into the skin.

Wikipedia : 74 Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about 3 people per... more...

Related Diseases for Merkel Cell Carcinoma

Diseases related to Merkel Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 755, show less)
# Related Disease Score Top Affiliating Genes
1 skin benign neoplasm 32.0 KRT7 KRT20 ENO2
2 eyelid carcinoma 32.0 KRT7 KRT20
3 skin carcinoma 31.7 TP53 KRT8 KRT7 KRT20 CHGA CD274
4 neuroendocrine tumor 31.5 SYP SST NKX2-1 NCAM1 KRT20 ENO2
5 lung oat cell carcinoma 31.4 SYP ENO2 CHGA
6 in situ carcinoma 31.2 TP53 MUC1 KRT8
7 meibomian cyst 31.1 KRT7 KRT20
8 leukemia, chronic lymphocytic 31.0 TP53 PTPRC PAX5 NCAM1 KIT CD274
9 ganglioneuroblastoma 30.9 TP53 SYP ENO2
10 basal cell carcinoma 30.8 TP53 SYP NCAM1 KRT8 KRT7 KRT20
11 lymphoblastic lymphoma 30.8 TP53 PTPRC PAX5
12 neuroendocrine carcinoma 30.8 SYP SST PTPRC PAX5 NKX2-1 NCAM1
13 eyelid benign neoplasm 30.8 KRT20 CHGA
14 cll/sll 30.7 TP53 PDCD1 PAX5
15 paget disease, extramammary 30.7 MUC1 KRT7 KRT20
16 malignant syringoma 30.7 KRT7 KRT20
17 keratinizing squamous cell carcinoma 30.7 TP53 NKX2-1 KRT7
18 dermatofibrosarcoma protuberans 30.7 TP53 KIT ENO2
19 sweat gland cancer 30.6 TP53 SYP KRT8 KRT7 KRT20
20 somatostatinoma 30.6 SST ENO2 CHGA
21 dendritic cell tumor 30.6 PTPRC MUC1 KRT20
22 adenocarcinoma 30.6 TP53 NKX2-1 MUC1 KRT7 KRT20 KIT
23 neurilemmoma 30.6 MUC1 KIT ENO2
24 rhabdomyosarcoma 30.6 TP53 SYP PTPRC KIT ENO2
25 oligodendroglioma 30.6 TP53 SYP ENO2 CHGA
26 pancytopenia 30.5 TP53 PTPRC NCAM1 KIT
27 thyroid carcinoma, familial medullary 30.5 SST NKX2-1 CHGA
28 neurofibroma 30.5 TP53 SYP MUC1 KIT
29 sarcoma 30.5 TP53 PTPRC MUC1 KIT KDR ENO2
30 mucosal melanoma 30.5 KIT KDR CD274
31 carcinosarcoma 30.5 TP53 MUC1 KRT7 KIT
32 thyroid gland medullary carcinoma 30.5 SST KDR CHGA
33 lymphoma, non-hodgkin, familial 30.4 TP53 PTPRC PAX5 NCAM1 CD274
34 pleomorphic adenoma 30.4 TP53 MUC1 KRT7
35 ewing sarcoma 30.4 TP53 SYP PTPRC NCAM1 KIT ENO2
36 carcinoid tumors, intestinal 30.4 SYP SST NKX2-1 ENO2 CHGA
37 exanthem 30.3 PDCD1 KIT KDR CD274
38 mammary paget's disease 30.3 MUC1 KRT8 KRT7 KRT20 CD274
39 adenoma 30.2 TP53 SYP SST MUC1 KRT7 KRT20
40 sarcoma, synovial 30.2 MUC1 KRT8 KRT7 KIT
41 spindle cell carcinoma 30.2 SYP MUC1 KRT8 KRT7 ENO2 CHGA
42 meningioma, familial 30.2 TP53 SYP SST ENO2
43 papillary carcinoma 30.2 SYP NKX2-1 MUC1 KRT7 KRT20 CHGA
44 wilms tumor 1 30.2 TP53 SYP NCAM1 KRT7 KIT ENO2
45 paraganglioma 30.2 SYP SST NCAM1 KIT ENO2 CHGA
46 lung benign neoplasm 30.2 TP53 SYP NKX2-1 NCAM1 KRT7 KRT20
47 angiosarcoma 30.1 TP53 MUC1 KRT8 KRT7 KIT KDR
48 diffuse large b-cell lymphoma 30.1 TP53 PTPRC PDCD1 PAX5 CD274
49 hemangioma 30.0 TP53 SYP NKX2-1 MUC1 KRT7 KIT
50 neuroblastoma 30.0 TP53 SYP SST NCAM1 MAP2 KIT
51 pancreatic adenocarcinoma 30.0 TP53 SST MUC1 KIT KDR CHGA
52 small cell carcinoma 30.0 TP53 SYP PTPRC NKX2-1 NCAM1 MUC1
53 pheochromocytoma 30.0 SYP SST NCAM1 KRT7 KIT KDR
54 small cell cancer of the lung 29.9 TP53 SYP SST PTPRC NKX2-1 NCAM1
55 lymphoma 29.9 TP53 PTPRC PDCD1 PAX5 MUC1 KIT
56 hematologic cancer 29.9 TP53 PTPRC PAX5 NCAM1 KIT KDR
57 myeloma, multiple 29.8 TP53 PTPRC PAX5 NCAM1 MUC1 KIT
58 large cell neuroendocrine carcinoma 29.7 SYP NKX2-1 NCAM1 KRT7 KRT20 KIT
59 gastrointestinal stromal tumor 29.7 TP53 SYP SST NCAM1 KIT KDR
60 leukemia, acute myeloid 29.6 TP53 PTPRC PAX5 NCAM1 KIT KDR
61 medulloblastoma 29.4 TP53 SYP PAX5 NCAM1 MAP2 KIT
62 lung cancer susceptibility 3 28.9 TP53 PDCD1 NKX2-1 MUC1 KRT8 KRT7
63 renal cell carcinoma, nonpapillary 28.7 TP53 PDCD1 NKX2-1 MUC1 KRT8 KRT7
64 lung cancer 28.6 TP53 SYP PTPRC PDCD1 NKX2-1 NCAM1
65 rare tumor 10.8
66 papillary ependymoma 10.7 SYP ENO2
67 malignant melanocytic neoplasm of the peripheral nerve sheath 10.7 SYP ENO2
68 nonmucinous bronchioloalveolar adenocarcinoma 10.7 NKX2-1 KRT20
69 primary hepatic neuroendocrine carcinoma 10.7 SYP CHGA
70 ovary neuroendocrine neoplasm 10.7 SYP KRT7
71 lung meningioma 10.7 SYP NKX2-1
72 urethral villous adenoma 10.7 KRT7 KRT20
73 pilomatrix carcinoma 10.7 MUC1 ENO2
74 reticular perineurioma 10.7 MUC1 KIT
75 vaginal glandular tumor 10.7 ENO2 CHGA
76 axillary lipoma 10.7 MUC1 KIT
77 scrotum paget's disease 10.7 MUC1 KRT7
78 intracranial cysts 10.7 MUC1 ENO2
79 cerebral neuroblastoma 10.7 SYP ENO2
80 acinar cell cystadenocarcinoma 10.7 SYP CHGA
81 cervical large cell neuroendocrine carcinoma 10.7 SYP CHGA
82 lung acinar adenocarcinoma 10.7 NKX2-1 KRT20
83 gastric signet ring cell adenocarcinoma 10.7 KRT7 KRT20
84 nephrogenic adenoma of urinary bladder 10.7 KRT7 KRT20
85 intrahepatic bile duct adenoma 10.7 KRT7 KRT20
86 ureter adenocarcinoma 10.7 NKX2-1 KRT7
87 seminal vesicle adenocarcinoma 10.7 KRT7 KRT20
88 atrophic vulva 10.7 KRT7 KRT20
89 mixed ductal-endocrine carcinoma 10.7 SYP CHGA
90 mucinous adenofibroma 10.7 SYP KRT7
91 lung combined type small cell carcinoma 10.6 SYP NCAM1
92 intracranial primitive neuroectodermal tumor 10.6 SYP ENO2
93 anus basaloid carcinoma 10.6 KRT7 KIT
94 gallbladder signet ring cell adenocarcinoma 10.6 MUC1 KRT7
95 cervical adenoid cystic carcinoma 10.6 KRT7 KIT
96 vulva adenocarcinoma 10.6 KRT7 KRT20
97 fallopian tube carcinosarcoma 10.6 TP53 NCAM1
98 rete testis neoplasm 10.6 NKX2-1 KRT7
99 nodular prostate 10.6 SYP ENO2
100 breast neuroendocrine neoplasm 10.6 SYP ENO2 CHGA
101 cystitis cystica 10.6 KRT7 KRT20
102 breast papillary carcinoma 10.6 SYP CHGA
103 neuroma 10.6 MUC1 KIT ENO2
104 rete testis adenocarcinoma 10.6 NKX2-1 KRT7
105 appendix carcinoid tumor 10.6 SYP ENO2 CHGA
106 sarcomatoid transitional cell carcinoma 10.6 TP53 SYP
107 auditory system cancer 10.6 SYP ENO2 CHGA
108 hypoganglionosis 10.6 SYP NCAM1
109 cauda equina neoplasm 10.6 SYP ENO2 CHGA
110 pituicytoma 10.6 NKX2-1 MAP2
111 vulvar eccrine porocarcinoma 10.6 SYP MUC1 CHGA
112 pineocytoma 10.6 SYP ENO2 CHGA
113 pineal region teratoma 10.6 SYP KIT ENO2
114 glomangiosarcoma 10.6 SYP NCAM1
115 cervix small cell carcinoma 10.6 SYP ENO2 CHGA
116 nodular hidradenoma 10.6 MUC1 KRT7
117 cerebral primitive neuroectodermal tumor 10.6 SYP MUC1
118 spindle cell thymoma 10.6 MUC1 ENO2
119 sinonasal undifferentiated carcinoma 10.6 SYP MUC1 ENO2
120 female urethral cancer 10.6 KRT7 KRT20 CHGA
121 ceruminous adenocarcinoma 10.6 KRT7 KIT
122 gastric gastrinoma 10.6 ENO2 CHGA
123 nodular ganglioneuroblastoma 10.6 ENO2 CHGA
124 mucinous intrahepatic cholangiocarcinoma 10.6 MUC1 KRT7
125 endobronchial leiomyoma 10.6 SYP KIT ENO2
126 papillary thymic adenocarcinoma 10.6 SYP NCAM1 CHGA
127 mucinous bronchioloalveolar adenocarcinoma 10.6 NKX2-1 KRT7 KRT20
128 esophageal adenoid cystic carcinoma 10.6 SYP NCAM1 CHGA
129 ovarian seromucinous carcinoma 10.6 TP53 KRT7
130 urinary bladder villous adenoma 10.6 MUC1 KRT7 KRT20
131 frontal lobe neoplasm 10.6 TP53 SYP ENO2
132 clear cell meningioma 10.6 SYP MUC1 CHGA
133 central epithelioid sarcoma 10.6 SYP KRT7 KRT20
134 vulvar proximal-type epithelioid sarcoma 10.6 SYP KRT7 KRT20
135 ovarian germ cell teratoma 10.6 SYP NKX2-1 KRT7
136 meningeal melanocytoma 10.6 MUC1 ENO2
137 mucinous ovarian cystadenoma 10.6 KRT7 KRT20
138 bile duct cystadenocarcinoma 10.6 MUC1 KRT7 KRT20
139 pulmonary large cell neuroendocrine carcinoma 10.6 SYP NCAM1 CHGA
140 colonic lymphangioma 10.6 MUC1 KRT7 KRT20
141 plexiform schwannoma 10.6 KIT ENO2
142 clear cell ependymoma 10.6 SYP MUC1 ENO2
143 rectosigmoid junction neoplasm 10.6 KRT7 KRT20
144 ureter transitional cell carcinoma 10.6 NCAM1 ENO2 CHGA
145 cervical adenocarcinoma 10.6 TP53 KRT7 KRT20
146 malignant teratoma 10.6 SYP KIT ENO2
147 sigmoid neoplasm 10.6 KRT7 KRT20
148 spinal cord oligodendroglioma 10.6 TP53 SYP ENO2
149 jejunal cancer 10.6 KRT7 KRT20
150 apocrine adenocarcinoma 10.6 TP53 MUC1 KRT7
151 papillary transitional carcinoma 10.6 TP53 KRT7 KRT20
152 pancreatic mucinous cystadenoma 10.6 MUC1 KRT7 KRT20
153 myxoid chondrosarcoma 10.6 SYP MUC1 CHGA
154 jejunal adenocarcinoma 10.6 KRT7 KRT20
155 ovarian small cell carcinoma 10.6 SYP MUC1 ENO2
156 central nervous system primitive neuroectodermal neoplasm 10.6 TP53 SYP ENO2
157 linitis plastica 10.6 MUC1 KRT7 KRT20
158 lung adenoid cystic carcinoma 10.6 KRT7 KIT
159 eccrine sweat gland cancer 10.6 TP53 KRT7 KRT20
160 adenofibroma 10.6 TP53 MUC1 KRT7
161 orbital cancer 10.6 SYP NCAM1 ENO2
162 endobronchial lipoma 10.6 SYP KRT7 ENO2
163 astroblastoma 10.6 SYP MUC1 ENO2
164 mucinous stomach adenocarcinoma 10.6 NKX2-1 KRT7 KIT
165 parachordoma 10.6 MUC1 KRT7 CHGA
166 non-functioning pancreatic endocrine tumor 10.6 SST CHGA
167 spinal cancer 10.6 TP53 SYP ENO2
168 fibrous histiocytoma 10.6 TP53 KIT ENO2
169 urethral benign neoplasm 10.6 TP53 KRT7 KRT20
170 granular cell tumor 10.6 SYP NKX2-1 ENO2
171 non-gestational ovarian choriocarcinoma 10.6 TP53 NCAM1
172 breast leiomyosarcoma 10.6 KRT7 KIT ENO2
173 bladder clear cell adenocarcinoma 10.6 TP53 KRT7 KRT20
174 clear cell adenocarcinoma 10.6 TP53 KRT7 KRT20
175 pancreatic foamy gland adenocarcinoma 10.6 TP53 MUC1 KRT7
176 cerebrum cancer 10.6 TP53 SYP ENO2
177 cecal disease 10.6 SYP KRT7 CHGA
178 cerebral ventricle cancer 10.6 TP53 SYP ENO2
179 squamous cell carcinoma 10.6
180 monoclonal paraproteinemia 10.6 PAX5 NCAM1
181 benign perivascular tumor 10.6 SYP KIT
182 borst-jadassohn intraepidermal carcinoma 10.6 TP53 KRT7 KRT20
183 supratentorial cancer 10.6 TP53 SYP ENO2
184 primitive neuroectodermal tumor of the cervix uteri 10.6 PTPRC ENO2
185 gastrointestinal neuroendocrine benign tumor 10.6 SYP SST CHGA
186 non-functioning pituitary adenoma 10.6 SST MUC1
187 adrenal cortical adenoma 10.6 SYP ENO2 CHGA
188 gastric neuroendocrine neoplasm 10.6 SYP SST CHGA
189 myxopapillary ependymoma 10.6 SYP NCAM1 MUC1
190 adult teratoma 10.6 TP53 CHGA
191 small intestinal sarcoma 10.6 PTPRC KIT
192 benign mastocytoma 10.6 PTPRC KIT
193 sarcomatoid renal cell carcinoma 10.6 TP53 MUC1 KIT
194 pancreatic gastrinoma 10.6 SYP SST CHGA
195 gastrinoma 10.6 SYP SST CHGA
196 retroperitoneal hemangiopericytoma 10.6 KIT ENO2
197 gastrointestinal neuroendocrine tumor 10.6 SYP SST CHGA
198 collecting duct carcinoma 10.6 MUC1 KRT7 KRT20
199 endosalpingiosis 10.6 TP53 MUC1 KRT7
200 endodermal sinus tumor 10.6 KRT7 KIT CHGA
201 ampulla of vater adenocarcinoma 10.6 MUC1 KRT7 KRT20
202 benign ependymoma 10.6 SYP MUC1 ENO2
203 bronchiolo-alveolar adenocarcinoma 10.6 NKX2-1 KRT7 KRT20
204 binswanger's disease 10.6 SYP SST CHGA
205 polycystic liver disease 1 with or without kidney cysts 10.6 MUC1 KRT7 KRT20
206 inverted papilloma 10.6 TP53 KRT7 KRT20
207 pleomorphic rhabdomyosarcoma 10.6 TP53 SYP KRT7
208 spiradenoma 10.6 TP53 MUC1 KRT7
209 transverse colon cancer 10.6 KRT7 KRT20
210 connective tissue benign neoplasm 10.6 TP53 KIT ENO2
211 multifocal osteogenic sarcoma 10.6 TP53 PTPRC
212 sex cord-gonadal stromal tumor 10.6 NKX2-1 MUC1 KRT7
213 appendix lymphoma 10.6 SST ENO2 CHGA
214 adrenal medulla cancer 10.6 SYP SST CHGA
215 perineurioma 10.6 NCAM1 MUC1 KIT
216 ovarian serous adenofibroma 10.6 TP53 NCAM1 KRT7
217 clear cell sarcoma 10.6 SYP KIT ENO2
218 rectum neuroendocrine neoplasm 10.5 SYP SST KRT7
219 biliary papillomatosis 10.5 MUC1 KRT7
220 adenoid basal cell carcinoma 10.5 KRT7 KIT
221 acral lentiginous melanoma 10.5 MUC1 KIT CD274
222 meckel diverticulum 10.5 SST KIT CHGA
223 myoepithelial carcinoma 10.5 TP53 MUC1 KRT7
224 primary pigmented nodular adrenocortical disease 10.5 SYP NCAM1 CHGA
225 appendiceal neoplasm 10.5 KRT7 CHGA
226 tonsil cancer 10.5 TP53 KRT7 KIT
227 vaginal tubulovillous adenoma 10.5 SYP KRT7 KRT20 CHGA
228 appendix adenocarcinoma 10.5 SYP KRT7 KRT20 CHGA
229 pancreatic cystadenoma 10.5 SYP SST CHGA
230 retinoblastoma 10.5
231 familial retinoblastoma 10.5
232 vaginal adenoma 10.5 SYP KRT7 KRT20 CHGA
233 vaginal benign neoplasm 10.5 SYP KRT7 KRT20 CHGA
234 necrotizing sialometaplasia 10.5 TP53 KRT7
235 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.5 SYP PTPRC ENO2
236 achalasia 10.5 TP53 KIT ENO2
237 anus cancer 10.5 TP53 KRT7 CD274
238 myxofibrosarcoma 10.5 TP53 MUC1 KIT
239 pituitary carcinoma 10.5 TP53 SST CHGA
240 ewing sarcoma of bone 10.5 PTPRC ENO2 CHGA
241 rosette-forming glioneuronal tumor 10.5 SYP MAP2
242 krukenberg carcinoma 10.5 SYP MUC1 KRT7 KRT20
243 bladder lateral wall cancer 10.5 SYP KRT7 KRT20 ENO2
244 gallbladder benign neoplasm 10.5 TP53 KRT7
245 microcystic adenoma 10.5 SYP MUC1 ENO2 CHGA
246 primary cutaneous anaplastic large cell lymphoma 10.5 PTPRC MUC1
247 thymus clear cell carcinoma 10.5 NKX2-1 KRT7 KRT20 KIT
248 salivary gland disease 10.5 TP53 KRT7 KIT
249 perivascular epithelioid cell tumor 10.5 SYP NKX2-1 MUC1 KIT
250 cystic basal cell carcinoma 10.5 SYP KRT7 KRT20 ENO2
251 pulmonary vein stenosis 10.5 KIT KDR
252 gastric small cell carcinoma 10.5 SYP NCAM1 ENO2 CHGA
253 subependymoma 10.5 SYP NCAM1 ENO2 CHGA
254 esophageal neuroendocrine tumor 10.5 SYP NCAM1 MUC1 CHGA
255 cervical neuroblastoma 10.5 SYP NCAM1 ENO2 CHGA
256 small intestine cancer 10.5 TP53 MUC1 KRT7
257 ovarian germ cell cancer 10.5 SYP NKX2-1 KRT7 KIT
258 bile duct mucinous adenocarcinoma 10.5 TP53 SYP MUC1 ENO2
259 type c thymoma 10.5 SST KIT
260 extracranial neuroblastoma 10.5 SYP NCAM1 ENO2 CHGA
261 muscle cancer 10.5 TP53 SYP KIT ENO2
262 breast lipoma 10.5 PTPRC PAX5
263 myoblastoma 10.5 SYP ENO2
264 lung large cell carcinoma 10.5 SYP NKX2-1 NCAM1 CHGA
265 clear cell basal cell carcinoma 10.5 TP53 KRT7 KRT20 CHGA
266 hemangiopericytoma, malignant 10.5 SYP MUC1 KIT ENO2
267 cranial nerve neoplasm 10.5 SYP NCAM1 ENO2 CHGA
268 laryngeal neuroendocrine tumor 10.5 TP53 SYP NCAM1 CHGA
269 intratubular embryonal carcinoma 10.5 TP53 KRT7 KRT20 KIT
270 chordoid meningioma 10.5 SYP NCAM1 MUC1 CHGA
271 central nervous system benign neoplasm 10.5 TP53 SYP ENO2 CHGA
272 liver leiomyosarcoma 10.5 KRT7 KIT ENO2 CHGA
273 vulva cancer 10.5 TP53 KRT7 CD274
274 differentiated thyroid carcinoma 10.5 TP53 NKX2-1 CD274
275 cystitis 10.5 TP53 KRT7 KRT20 KIT
276 duodenum disease 10.5 SST MUC1 KRT7
277 urethra transitional cell carcinoma 10.5 TP53 PTPRC
278 pineal parenchymal tumor of intermediate differentiation 10.5 SYP ENO2
279 adrenal cortical carcinoma 10.5 TP53 SYP MUC1 CHGA
280 papillary adenoma 10.5 TP53 SYP NKX2-1 KRT7
281 papillary serous adenocarcinoma 10.5 TP53 NKX2-1 KRT7 KRT20
282 melanoma 10.5
283 acinar cell carcinoma 10.5 TP53 SYP KRT7 CHGA
284 glomus tumor 10.5 TP53 SYP MUC1 ENO2
285 glandular cystitis 10.5 TP53 MUC1 KRT7 KRT20
286 lymphoepithelioma-like thymic carcinoma 10.5 KRT8 KIT
287 cerebrovascular benign neoplasm 10.5 TP53 SYP KRT7 ENO2
288 optic nerve astrocytoma 10.5 SYP ENO2
289 atypical teratoid rhabdoid tumor 10.5 TP53 SYP MUC1 CHGA
290 appendix disease 10.5 TP53 MUC1 KRT7 KRT20
291 gastric diffuse adenocarcinoma 10.5 TP53 MUC1 KRT7 KRT20
292 appendix cancer 10.5 TP53 MUC1 KRT7 KRT20
293 proliferating trichilemmal cyst 10.5 KRT8 KRT7
294 endolymphatic sac tumor 10.5 KRT8 KRT7
295 ovarian benign neoplasm 10.5 TP53 MUC1 KRT7 KRT20
296 mesenchymal chondrosarcoma 10.5 SYP MUC1 KRT7 ENO2
297 sertoli-leydig cell tumor 10.5 SYP MUC1 KRT7 ENO2
298 epithelioid leiomyosarcoma 10.5 PTPRC MUC1 ENO2
299 calcifying epithelial odontogenic tumor 10.5 TP53 KRT8
300 pseudomyxoma peritonei 10.5 TP53 MUC1 KRT7 KRT20
301 lipoadenoma 10.5 MUC1 KRT7
302 bile duct adenoma 10.5 NCAM1 MUC1 KRT7 KRT20
303 endocervical adenocarcinoma 10.5 TP53 MUC1 KRT7 KRT20
304 duodenal benign neoplasm 10.5 SYP SST ENO2 CHGA
305 ampulla of vater neoplasm 10.5 SYP SST ENO2 CHGA
306 central nervous system lymphoma 10.5 TP53 PAX5 CD274
307 endometrial adenocarcinoma 10.5 TP53 MUC1 KRT7
308 pancreatic ductal carcinoma 10.5 TP53 MUC1 KRT7 KRT20
309 carcinoid syndrome 10.5 SYP SST ENO2 CHGA
310 ampulla of vater cancer 10.5 TP53 MUC1 KRT7 KRT20
311 duodenal gastrinoma 10.5 SST CHGA
312 bowen's disease 10.5
313 autonomic nervous system benign neoplasm 10.5 SYP SST ENO2 CHGA
314 peripheral nervous system benign neoplasm 10.5 SYP SST ENO2 CHGA
315 papillary adenocarcinoma 10.5 TP53 NKX2-1 MUC1 KRT7
316 ovary adenocarcinoma 10.5 TP53 MUC1 KRT7 KRT20
317 well-differentiated liposarcoma 10.5 TP53 MUC1 KRT7 KIT
318 chiari malformation 10.5 SYP MAP2
319 pancreatoblastoma 10.5 SYP SST MUC1 CHGA
320 inflammatory myofibroblastic tumor 10.5 TP53 MUC1 KIT ENO2
321 pneumothorax 10.5 NKX2-1 MUC1 KDR
322 biliary tract benign neoplasm 10.5 TP53 NCAM1 MUC1 KRT7
323 rectum adenocarcinoma 10.5 TP53 KRT7 KRT20 CD274
324 subareolar duct papillomatosis 10.5 KRT8 KRT7
325 ovarian serous cystadenofibroma 10.5 TP53 NCAM1 MUC1 KRT7
326 dedifferentiated liposarcoma 10.5 TP53 MUC1 KIT
327 goblet cell carcinoid 10.5 KRT20 ENO2 CHGA ATOH1
328 nipple benign neoplasm 10.5 KRT8 KRT7
329 islet cell tumor 10.5 SYP SST ENO2 CHGA
330 benign breast adenomyoepithelioma 10.5 KRT8 KRT7
331 anal neuroendocrine tumor 10.5 SYP SST NCAM1 ENO2
332 breast hemangioma 10.4 TP53 KRT7
333 pancreatic endocrine carcinoma 10.4 SYP SST NCAM1 CHGA
334 mesothelioma, malignant 10.4 NKX2-1 MUC1 KRT7 KRT20
335 central neurocytoma 10.4 SYP MAP2 ENO2 CHGA
336 papillary tumor of the pineal region 10.4 SYP MUC1 MAP2 ENO2
337 stomach disease 10.4 TP53 SST CHGA
338 adrenal gland disease 10.4 TP53 SYP SST CHGA
339 bile duct mucoepidermoid carcinoma 10.4 MUC1 KRT7
340 reticulosarcoma 10.4 PTPRC PAX5 MUC1
341 pleomorphic xanthoastrocytoma 10.4 TP53 SYP MAP2 CHGA
342 nodular lymphocyte predominant hodgkin lymphoma 10.4 PDCD1 PAX5
343 oropharynx cancer 10.4 TP53 KRT7 KIT CD274
344 neurofibromatosis, type i 10.4 SST NCAM1 KIT
345 intestinal obstruction 10.4 SST KRT7 KRT20 KIT
346 angiomyolipoma 10.4 PTPRC KRT7 KIT
347 malignant pleural mesothelioma 10.4 TP53 NKX2-1 MUC1 CD274
348 malignant peripheral nerve sheath tumor 10.4 TP53 MUC1 KRT7 KIT
349 cerebellum cancer 10.4 TP53 SYP ENO2 ATOH1
350 cerebellar medulloblastoma 10.4 TP53 SYP ENO2 ATOH1
351 eccrine papillary adenocarcinoma 10.4 SYP KRT8 KRT7
352 adenoid squamous cell carcinoma 10.4 KRT8 KRT7 KRT20
353 vulvar apocrine adenocarcinoma 10.4 PTPRC KRT7 KRT20 ENO2
354 breast osteosarcoma 10.4 KRT8 KRT7 KRT20
355 jejunal neoplasm 10.4 SYP KRT7 KRT20 KIT ENO2
356 keratosis 10.4
357 atrophic gastritis 10.4 TP53 SST MUC1 CHGA
358 duodenum cancer 10.4 TP53 SST MUC1 KRT7
359 laryngeal small cell carcinoma 10.4 SYP NKX2-1 NCAM1 KIT CHGA
360 cutaneous adenocystic carcinoma 10.4 NKX2-1 KRT8 KRT7
361 cerebellopontine angle primitive neuroectodermal tumor 10.4 SYP PTPRC NCAM1 ENO2
362 pulmonary sclerosing hemangioma 10.4 SYP NKX2-1 KRT7 ENO2 CHGA
363 colon neuroendocrine neoplasm 10.4 SYP NKX2-1 NCAM1 ENO2 CHGA
364 pancreatic serous cystadenocarcinoma 10.4 SYP NCAM1 KRT7 KRT20 CHGA
365 medulloepithelioma 10.4 SYP MUC1 KRT7 KRT20 ENO2
366 rhabdoid tumor predisposition syndrome 1 10.4 TP53 SYP PTPRC MUC1
367 middle ear adenoma 10.4 SYP MUC1 KRT7 ENO2 CHGA
368 mucinous cystadenocarcinoma 10.4 PTPRC MUC1 KRT7 KRT20
369 gastrointestinal system benign neoplasm 10.4 TP53 SST KRT7 CHGA
370 cribriform carcinoma 10.4 KRT8 KRT7 KIT
371 mucinous tubular and spindle renal cell carcinoma 10.4 MUC1 KRT8 KRT7
372 conventional fibrosarcoma 10.4 TP53 PTPRC KIT ENO2
373 pleomorphic liposarcoma 10.4 MUC1 KRT8 KIT
374 granulosa cell tumor of the ovary 10.4 TP53 SYP KRT7 ENO2 CHGA
375 gliosarcoma 10.4 TP53 SYP KDR ENO2
376 gastrointestinal carcinoma 10.4 TP53 PTPRC MUC1 KRT20
377 cystadenocarcinoma 10.4 TP53 PTPRC MUC1 KRT7
378 bone lymphoma 10.4 PTPRC PAX5
379 signet ring cell adenocarcinoma 10.4 TP53 MUC1 KRT7 KRT20 CHGA
380 auditory system benign neoplasm 10.4 SYP NCAM1 KRT7 ENO2 CHGA
381 gallbladder small cell carcinoma 10.4 SYP NCAM1 KRT7 ENO2 CHGA
382 sensory organ benign neoplasm 10.4 SYP NCAM1 KRT7 ENO2 CHGA
383 chordoid glioma 10.4 TP53 SYP NKX2-1 MUC1 KRT7
384 mature teratoma 10.4 TP53 SYP KRT7 KIT ENO2
385 dysgerminoma 10.4 MUC1 KRT7 KRT20 KIT ENO2
386 glucagonoma 10.4 SST CHGA
387 nasal cavity olfactory neuroblastoma 10.4 SYP NKX2-1 NCAM1 KRT7 ENO2
388 sweat gland benign neoplasm 10.4 TP53 KRT8 KRT7
389 fibrolamellar carcinoma 10.4 SYP KRT8 KRT7
390 papilloma of choroid plexus 10.4 TP53 SYP MUC1 KRT7 ENO2
391 solid adenocarcinoma with mucin production 10.4 NKX2-1 NCAM1 MUC1 KRT7 CHGA
392 malignant fibrous histiocytoma 10.4 TP53 PTPRC MUC1 KIT
393 carotid body cancer 10.4 SYP SST NKX2-1 ENO2 CHGA
394 skeletal muscle cancer 10.4 TP53 SYP NCAM1 KIT ENO2
395 sweat gland disease 10.4 TP53 KRT8 KRT7
396 mucoepidermoid carcinoma 10.4 TP53 NKX2-1 MUC1 KRT7 CHGA
397 cerebellar liponeurocytoma 10.4 SYP MAP2 ENO2 ATOH1
398 breast adenocarcinoma 10.4 TP53 SYP ENO2 CHGA
399 small intestine benign neoplasm 10.4 SYP SST KIT ENO2 CHGA
400 vulvar disease 10.4 TP53 KRT7 KRT20 KIT CD274
401 peripheral nervous system neoplasm 10.4 TP53 SYP NCAM1 KIT ENO2
402 renal cell carcinoma, papillary, 1 10.4 TP53 KRT7 KIT KDR
403 intrahepatic gall duct cancer 10.4 KRT8 KRT7
404 pulmonary blastoma 10.4 TP53 SYP SST NKX2-1 CHGA
405 b-cell lymphoma 10.4
406 actinic keratosis 10.4
407 chromosomal triplication 10.4
408 ganglioneuroma 10.4 SYP SST NCAM1 ENO2 CHGA
409 plasmacytoma 10.4 SYP PTPRC PAX5 NCAM1
410 intrahepatic cholangiocarcinoma 10.4 TP53 MUC1 KRT7 KRT20 CD274
411 mixed oligodendroglioma-astrocytoma 10.4 TP53 PDCD1 CD274
412 leukocyte disease 10.3 TP53 PTPRC NCAM1 KIT
413 plasma cell neoplasm 10.3 TP53 PTPRC PAX5 NCAM1
414 malignant pheochromocytoma 10.3 SYP SST NCAM1 ENO2 CHGA
415 bone marrow cancer 10.3 TP53 PTPRC NCAM1 KIT
416 endocrine organ benign neoplasm 10.3 TP53 SYP SST ENO2 CHGA
417 adrenal carcinoma 10.3 TP53 SYP SST ENO2 CHGA
418 pancreatic cholera 10.3 SST CHGA
419 anaplastic large cell lymphoma 10.3 PTPRC PAX5 MUC1 ENO2
420 wolffian duct adenocarcinoma 10.3 TP53 KRT7
421 cardiovascular organ benign neoplasm 10.3 TP53 SYP KDR ENO2 CHGA
422 olfactory neuroblastoma 10.3 SYP PTPRC NKX2-1 ENO2 CHGA
423 brooke-spiegler syndrome 10.3 TP53 KRT8 KRT7
424 papilloma 10.3 TP53 KRT8 KRT7 KRT20
425 mature b-cell neoplasm 10.3 TP53 PTPRC PAX5 NCAM1
426 tuberous sclerosis 10.3 TP53 SYP SST ENO2 CHGA
427 lymph node disease 10.3
428 prostate stromal sarcoma 10.3 SYP NCAM1 KRT8 KIT
429 sarcomatous intrahepatic cholangiocarcinoma 10.3 NKX2-1 KRT8 KRT7 KIT
430 cheilitis 10.3 TP53 PDCD1 CD274
431 ganglioglioma 10.3 TP53 SYP MAP2 ENO2 CHGA
432 combined t cell and b cell immunodeficiency 10.3 TP53 PTPRC NCAM1 KIT
433 retroperitoneum carcinoma 10.3 SYP PTPRC KRT7 KRT20 KIT
434 cardiovascular cancer 10.3 TP53 SYP KRT7 KIT KDR
435 vascular cancer 10.3 TP53 SYP KRT7 KIT KDR
436 small cell carcinoma of the bladder 10.3 SYP NKX2-1 KRT7 KRT20 ENO2 CHGA
437 extraskeletal ewing sarcoma 10.3 SYP PTPRC NKX2-1 MUC1 ENO2
438 horseshoe kidney 10.3 SYP NKX2-1 KRT7 KRT20 ENO2 CHGA
439 squamous cell bile duct carcinoma 10.3 KRT8 KRT7
440 cutaneous ganglioneuroma 10.3 SYP NCAM1 KRT20 KIT ENO2 CHGA
441 peritoneal serous adenocarcinoma 10.3 TP53 SYP NKX2-1 KRT7 KRT20 CHGA
442 olfactory nerve neoplasm 10.3 SYP PTPRC NCAM1 ENO2 CHGA
443 cranial nerve malignant neoplasm 10.3 SYP PTPRC NCAM1 ENO2 CHGA
444 epithelioid sarcoma 10.3 SYP MUC1 KRT8 KRT7
445 gallbladder cancer 10.3 TP53 MUC1 KRT7 KRT20 CD274
446 cystadenoma 10.3 SYP MUC1 KRT7 KRT20 KIT CHGA
447 chordoma 10.3 TP53 NCAM1 MUC1 KRT7 CD274
448 ovarian brenner tumor 10.3 KRT7 KRT20
449 leiomyosarcoma 10.3 TP53 PTPRC MUC1 KIT ENO2
450 skin melanoma 10.3
451 sclerosing hemangioma 10.3 SYP NKX2-1 MUC1 KRT7 ENO2 CHGA
452 urinary bladder small cell neuroendocrine carcinoma 10.3 SYP NCAM1 KRT7 KRT20 ENO2 CHGA
453 ovarian large-cell neuroendocrine carcinoma 10.3 SYP NCAM1 KRT7 KRT20 ENO2 CHGA
454 thoracic benign neoplasm 10.3 TP53 MUC1 KRT8 KRT7
455 breast benign neoplasm 10.3 TP53 MUC1 KRT8 KRT7
456 endocrine gland cancer 10.3 SYP SST KDR CHGA
457 lung non-squamous non-small cell carcinoma 10.3 PDCD1 KDR CD274
458 respiratory system benign neoplasm 10.3 TP53 SYP NKX2-1 KRT7 ENO2 CHGA
459 gastroesophageal junction adenocarcinoma 10.3 PDCD1 KDR CD274
460 hirschsprung disease 1 10.3 SYP NCAM1 KIT KDR ENO2
461 mixed cell type cancer 10.3 TP53 SYP KRT7 KIT ENO2 CHGA
462 ureter small cell carcinoma 10.3 SYP NKX2-1 NCAM1 KRT7 ENO2 CHGA
463 hodgkin's lymphoma, nodular sclerosis 10.3 PTPRC PAX5
464 pre-malignant neoplasm 10.3 TP53 MUC1 KRT8 KRT7
465 thymus gland disease 10.3 TP53 SYP PTPRC KIT CD274
466 synovium neoplasm 10.3 KRT8 KRT7
467 autoimmune disease 10.3
468 kaposi sarcoma 10.3
469 lymphoma, hodgkin, classic 10.3
470 lambert-eaton myasthenic syndrome 10.3
471 thyroid gland disease 10.3 SST NKX2-1 CD274
472 pulmonary neuroendocrine tumor 10.2 SYP SST NKX2-1 NCAM1 ENO2 CHGA
473 gastric hemangioma 10.2 SYP SST NCAM1 KIT ENO2 CHGA
474 subependymal giant cell astrocytoma 10.2 SYP SST NKX2-1 NCAM1 ENO2 CHGA
475 myeloid sarcoma 10.2 PTPRC PAX5 NCAM1 KIT CD274
476 cell type benign neoplasm 10.2 TP53 SYP SST KRT7 KIT CHGA
477 lentigines 10.2
478 melanoma, cutaneous malignant 10 10.2
479 neutropenia 10.2
480 amelanotic melanoma 10.2
481 lymphopenia 10.2
482 severe combined immunodeficiency 10.2
483 47,xyy 10.2
484 paraneoplastic syndromes 10.2
485 breast carcinoma in situ 10.2 TP53 KRT8 KDR
486 sertoli cell tumor 10.2 SYP MUC1 KRT8 KRT7 ENO2
487 mantle cell lymphoma 10.2 TP53 PTPRC PAX5 KIT CD274
488 endometrial small cell carcinoma 10.2 SYP PTPRC NCAM1 KIT ENO2 CHGA
489 endocrine pancreas disease 10.2 SST CHGA
490 transitional cell carcinoma 10.2 TP53 KRT8 KRT7 KRT20 ENO2
491 glomangiomatosis 10.2 TP53 SYP PTPRC NCAM1 KIT CHGA
492 cystic teratoma 10.2 TP53 SYP NKX2-1 KRT7 KRT20 KIT
493 breast ductal carcinoma 10.2 TP53 SYP MUC1 KRT8 KRT7
494 tubular adenocarcinoma 10.2 SYP NCAM1 MUC1 KRT7 KRT20 ENO2
495 breast cancer 10.2
496 epidermodysplasia verruciformis 1 10.2
497 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
498 cutaneous t cell lymphoma 10.2
499 leukemia 10.2
500 skin disease 10.2
501 insulinoma 10.2
502 spindle cell sarcoma 10.2
503 cerebellar degeneration 10.2
504 ureteral benign neoplasm 10.2 SYP KRT7
505 villous adenoma 10.2 TP53 SST MUC1 KRT8 KRT20
506 uterine carcinosarcoma 10.2 TP53 MUC1 KRT8 KIT CD274
507 hemangioblastoma 10.2 SYP MUC1 KRT8 KDR ENO2
508 thymus cancer 10.2 TP53 PTPRC NKX2-1 KRT7 KIT CD274
509 hidrocystoma 10.2 KRT8 KRT7
510 cavernous hemangioma 10.1 SYP NKX2-1 MUC1 KRT7 KRT20 KIT
511 bile duct cancer 10.1 TP53 NCAM1 MUC1 KRT7 KDR CD274
512 uterus leiomyosarcoma 10.1 SYP NKX2-1 KRT8 KRT7 KIT ENO2
513 mucinous adenocarcinoma 10.1 TP53 SST NKX2-1 MUC1 KRT7 KRT20
514 multiple sclerosis 10.1
515 sarcoidosis 1 10.1
516 immune deficiency disease 10.1
517 ataxia and polyneuropathy, adult-onset 10.1
518 hereditary lymphedema i 10.1
519 mucositis 10.1
520 thrombocytopenia 10.1
521 keratoacanthoma 10.1
522 sebaceous adenocarcinoma 10.1
523 cowden syndrome 10.1
524 posttransplant acute limbic encephalitis 10.1
525 benign teratoma 10.1 TP53 SYP NKX2-1 MUC1 KRT7 KRT20
526 cholangiocarcinoma 10.1 TP53 NCAM1 MUC1 KRT8 KRT7 KRT20
527 pleomorphic carcinoma 10.1 TP53 NKX2-1 KRT8 KRT7 KIT CD274
528 lipomatosis, multiple 10.0
529 systemic lupus erythematosus 10.0
530 cowden syndrome 1 10.0
531 keratosis, seborrheic 10.0
532 myasthenia gravis 10.0
533 mycosis fungoides 10.0
534 osteogenic sarcoma 10.0
535 rhabdomyosarcoma 2 10.0
536 psoriatic arthritis 10.0
537 helix syndrome 10.0
538 deficiency anemia 10.0
539 pleomorphic lipoma 10.0
540 cardiac tamponade 10.0
541 hypothyroidism 10.0
542 kidney cancer 10.0
543 dermatitis 10.0
544 embryonal rhabdomyosarcoma 10.0
545 paraplegia 10.0
546 acquired immunodeficiency syndrome 10.0
547 inverted follicular keratosis 10.0
548 eccrine porocarcinoma 10.0
549 myeloid leukemia 10.0
550 neurofibromatosis 10.0
551 paraneoplastic cerebellar degeneration 10.0
552 superficial spreading melanoma 10.0
553 back pain 10.0
554 dysphagia 10.0
555 pik3ca-related overgrowth syndrome 10.0
556 thyroid carcinoma 10.0
557 oncocytoma 10.0 SYP NKX2-1 MUC1 KRT8 KRT7 KRT20
558 basaloid squamous cell carcinoma 10.0 TP53 SYP KRT8 KRT7 KRT20 ENO2
559 lung disease 10.0 TP53 PDCD1 NKX2-1 MUC1 ENO2 CD274
560 hemangioma-thrombocytopenia syndrome 10.0
561 colorectal adenocarcinoma 10.0 TP53 NKX2-1 MUC1 KRT7 KRT20 KIT
562 bladder urothelial carcinoma 10.0 TP53 KRT7 KRT20 KIT HAVCR2 CD274
563 prostate neuroendocrine neoplasm 10.0 TP53 SYP PTPRC NCAM1 KRT7 KRT20
564 large cell carcinoma 10.0 SYP NKX2-1 NCAM1 MUC1 KRT7 KRT20
565 adenoid cystic carcinoma 10.0 TP53 NCAM1 MUC1 KRT8 KRT7 KRT20
566 melanoma, uveal 10.0 TP53 PDCD1 KRT8 KIT CD274
567 peripheral t-cell lymphoma 9.9 TP53 PTPRC PDCD1 PAX5 NCAM1 CD274
568 basal cell nevus syndrome 9.9
569 burkitt lymphoma 9.9
570 colorectal cancer 9.9
571 hepatocellular carcinoma 9.9
572 epidermoid cysts 9.9
573 esophageal cancer 9.9
574 lichen sclerosus et atrophicus 9.9
575 ocular cicatricial pemphigoid 9.9
576 piebald trait 9.9
577 pityriasis rubra pilaris 9.9
578 prostate cancer 9.9
579 dowling-degos disease 1 9.9
580 temporal arteritis 9.9
581 thrombocytopenic purpura, autoimmune 9.9
582 thyroid cancer, nonmedullary, 1 9.9
583 triiodothyronine receptor auxiliary protein 9.9
584 vitiligo-associated multiple autoimmune disease susceptibility 6 9.9
585 ataxia-telangiectasia 9.9
586 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.9
587 enterocolitis 9.9
588 myelofibrosis 9.9
589 polycythemia vera 9.9
590 skin/hair/eye pigmentation, variation in, 2 9.9
591 squamous cell carcinoma, head and neck 9.9
592 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.9
593 intervertebral disc disease 9.9
594 meningioma, radiation-induced 9.9
595 vitiligo-associated multiple autoimmune disease susceptibility 1 9.9
596 neutrophilic dermatosis, acute febrile 9.9
597 endometrial cancer 9.9
598 leukemia, chronic myeloid 9.9
599 aplastic anemia 9.9
600 human immunodeficiency virus type 1 9.9
601 diabetes mellitus, ketosis-prone 9.9
602 myelodysplastic syndrome 9.9
603 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
604 human herpesvirus 8 9.9
605 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
606 chronic ulcer of skin 9.9
607 hypophosphatemia 9.9
608 adult t-cell leukemia 9.9
609 female breast cancer 9.9
610 second-degree atrioventricular block 9.9
611 fibroma 9.9
612 adrenal gland pheochromocytoma 9.9
613 ptosis 9.9
614 oral hairy leukoplakia 9.9
615 lymphoproliferative syndrome 9.9
616 osteomyelitis 9.9
617 chronic leukemia 9.9
618 rickets 9.9
619 interstitial nephritis 9.9
620 thrombotic thrombocytopenic purpura 9.9
621 hydronephrosis 9.9
622 respiratory failure 9.9
623 arteriovenous malformation 9.9
624 erysipelas 9.9
625 spinal meningioma 9.9
626 hemopericardium 9.9
627 chondrocalcinosis 9.9
628 cauda equina syndrome 9.9
629 iron deficiency anemia 9.9
630 pericardial effusion 9.9
631 goiter 9.9
632 plica syndrome 9.9
633 von willebrand's disease 9.9
634 hepatic coma 9.9
635 telangiectasis 9.9
636 tolosa-hunt syndrome 9.9
637 pulmonary sarcoidosis 9.9
638 hepatic encephalopathy 9.9
639 obstructive jaundice 9.9
640 polyneuropathy 9.9
641 facial paralysis 9.9
642 sporotrichosis 9.9
643 candidiasis 9.9
644 lymphadenitis 9.9
645 rectum cancer 9.9
646 autoimmune hepatitis 9.9
647 constipation 9.9
648 ectodermal dysplasia 9.9
649 hepatitis 9.9
650 iron metabolism disease 9.9
651 relapsing-remitting multiple sclerosis 9.9
652 sensory peripheral neuropathy 9.9
653 agammaglobulinemia 9.9
654 synovitis 9.9
655 epidermolysis bullosa 9.9
656 contact dermatitis 9.9
657 hairy cell leukemia 9.9
658 laryngeal squamous cell carcinoma 9.9
659 testicular cancer 9.9
660 allergic contact dermatitis 9.9
661 gingivitis 9.9
662 multiple endocrine neoplasia 9.9
663 purpura 9.9
664 small cell osteogenic sarcoma 9.9
665 liposarcoma 9.9
666 cellulitis 9.9
667 duodenal obstruction 9.9
668 pituitary adenoma 9.9
669 hidradenoma 9.9
670 differentiating neuroblastoma 9.9
671 myopathy 9.9
672 nodular basal cell carcinoma 9.9
673 fibroepithelial basal cell carcinoma 9.9
674 pustulosis of palm and sole 9.9
675 cutaneous fibrous histiocytoma 9.9
676 seminoma 9.9
677 hypokalemia 9.9
678 skin angiosarcoma 9.9
679 secretory meningioma 9.9
680 lymphoplasmacyte-rich meningioma 9.9
681 epidermolysis bullosa simplex 9.9
682 uremia 9.9
683 histiocytoid hemangioma 9.9
684 klatskin's tumor 9.9
685 chronic inflammatory demyelinating polyradiculoneuropathy 9.9
686 demyelinating polyneuropathy 9.9
687 eyelid disease 9.9
688 eccrine acrospiroma 9.9
689 cellular myxoid liposarcoma 9.9
690 progressive multifocal leukoencephalopathy 9.9
691 compartment syndrome 9.9
692 t-cell lymphoblastic leukemia/lymphoma 9.9
693 thyroiditis 9.9
694 active peptic ulcer disease 9.9
695 chronic kidney disease 9.9
696 adult xanthogranuloma 9.9
697 periodontitis 9.9
698 polycythemia 9.9
699 bullous pemphigoid 9.9
700 collagen disease 9.9
701 sezary's disease 9.9
702 lip cancer 9.9
703 lupus erythematosus 9.9
704 psoriasis 9.9
705 macroglobulinemia 9.9
706 lichen planus 9.9
707 diabetes mellitus 9.9
708 intracranial hypertension 9.9
709 stomatitis 9.9
710 renal tuberculosis 9.9
711 hordeolum 9.9
712 hypoglycemia 9.9
713 albinism 9.9
714 48,xyyy 9.9
715 basal cell carcinoma, multiple 9.9
716 congenital extrahepatic portosystemic shunt 9.9
717 cutaneous sclerosis 9.9
718 cytokine deficiency 9.9
719 desmoplastic small round cell tumor 9.9
720 erythrokeratoderma ''en cocardes'' 9.9
721 hemangioendothelioma 9.9
722 lentigo maligna melanoma 9.9
723 leukemia, t-cell, chronic 9.9
724 leukoplakia 9.9
725 paraneoplastic neurologic disorders 9.9
726 pyogenic granuloma 9.9
727 radiation induced cancer 9.9
728 subacute cerebellar degeneration 9.9
729 triploidy 9.9
730 encephalopathy 9.9
731 myoclonus 9.9
732 syncope 9.9
733 inflammatory myopathy with abundant macrophages 9.9
734 partial deletion of the long arm of chromosome 7 9.9
735 partial duplication of chromosome 11 9.9
736 cancer-associated retinopathy 9.9
737 acute liver failure 9.9
738 eye disease 9.9 TP53 SST PTPRC KRT8 KDR
739 external ear carcinoma 9.9
740 argyria 9.9
741 mediastinal cancer 9.8 SYP PTPRC PAX5 NKX2-1 NCAM1 KRT7
742 leber plus disease 9.8 TP53 SYP PTPRC PAX5 NCAM1 KRT7
743 lymphoepithelioma-like carcinoma 9.8 PDCD1 MUC1 KRT8 KRT7 KRT20 ENO2
744 adenosquamous carcinoma 9.8 TP53 SYP NKX2-1 MUC1 KRT8 KRT7
745 thyroid gland cancer 9.8 TP53 SYP SST NKX2-1 KRT7 KRT20
746 teratoma 9.7 TP53 SYP SST NKX2-1 MAP2 KRT7
747 thymic carcinoma 9.7 TP53 SYP PTPRC NKX2-1 MUC1 KRT7
748 craniopharyngioma 9.7 KRT8 KRT7 CD274
749 chromophobe renal cell carcinoma 9.7 PDCD1 MUC1 KRT8 KRT7 KRT20 KIT
750 bladder cancer 9.7 TP53 PDCD1 MUC1 KRT8 KRT20 KDR
751 thymoma 9.7 TP53 SYP SST PTPRC NKX2-1 MUC1
752 clear cell renal cell carcinoma 9.6 TP53 PDCD1 MUC1 KRT7 KDR HAVCR2
753 pancreatic cancer 9.6 TP53 SST MUC1 KRT8 KRT7 KRT20
754 suppression of tumorigenicity 12 9.4 TP53 SYP PTPRC NCAM1 KRT8 KRT7
755 gastric adenocarcinoma 9.2 TP53 SST PDCD1 MUC1 KRT8 KRT7

Graphical network of the top 20 diseases related to Merkel Cell Carcinoma:



Diseases related to Merkel Cell Carcinoma

Symptoms & Phenotypes for Merkel Cell Carcinoma

Human phenotypes related to Merkel Cell Carcinoma:

58 31 (showing 17, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 merkel cell skin cancer 58 31 obligate (100%) Obligate (100%) HP:0030447
2 cutaneous photosensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0000992
3 cellular immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0005374
4 skin nodule 58 31 frequent (33%) Frequent (79-30%) HP:0200036
5 erythematous macule 58 31 frequent (33%) Frequent (79-30%) HP:0025475
6 chronic noninfectious lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002730
7 regional abnormality of skin 58 31 frequent (33%) Frequent (79-30%) HP:0011356
8 erythematous plaque 58 31 frequent (33%) Frequent (79-30%) HP:0025474
9 basal cell carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002671
10 squamous cell carcinoma of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0006739
11 multiple myeloma 58 31 occasional (7.5%) Occasional (29-5%) HP:0006775
12 carcinoid tumor 58 31 occasional (7.5%) Occasional (29-5%) HP:0100570
13 lymphoid leukemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0005526
14 abnormal brain fdg positron emission tomography 58 31 very rare (1%) Very rare (<4-1%) HP:0012658
15 brain neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0030692
16 neoplasm of the outer ear 58 31 very rare (1%) Very rare (<4-1%) HP:0040095
17 pain 58 Excluded (0%)

MGI Mouse Phenotypes related to Merkel Cell Carcinoma:

45 (showing 10, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.26 ATOH1 CD274 ENO2 KDR KIT MAP2
2 cellular MP:0005384 10.25 ATOH1 CD274 ENO2 HAVCR2 KDR KIT
3 growth/size/body region MP:0005378 10.22 CHGA ENO2 HAVCR2 KDR KIT KRT8
4 mortality/aging MP:0010768 10.2 ATOH1 CD274 CHGA HAVCR2 KDR KIT
5 homeostasis/metabolism MP:0005376 10.18 ATOH1 CD274 CHGA KDR KIT KRT7
6 cardiovascular system MP:0005385 10.16 CHGA HAVCR2 KDR KIT KRT8 NKX2-1
7 nervous system MP:0003631 10.1 ATOH1 CHGA ENO2 KDR KIT MAP2
8 no phenotypic analysis MP:0003012 9.81 ATOH1 CD274 CHGA KDR KIT NKX2-1
9 normal MP:0002873 9.61 ATOH1 KDR KIT NKX2-1 PAX5 PTPRC
10 respiratory system MP:0005388 9.23 ATOH1 ENO2 KDR KIT NKX2-1 PDCD1

Drugs & Therapeutics for Merkel Cell Carcinoma

Drugs for Merkel Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 78, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2 Anti-Bacterial Agents Phase 4
3 Antibiotics, Antitubercular Phase 4
4 Pharmaceutical Solutions Phase 3
5
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
6
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
7
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
8
lanreotide Approved Phase 2 108736-35-2
9
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
10
Durvalumab Approved, Investigational Phase 2 1428935-60-7
11
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
12
Cemiplimab Approved, Investigational Phase 1, Phase 2 1801342-60-8
13
Etoposide Approved Phase 2 33419-42-0 36462
14
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
15
nivolumab Approved Phase 1, Phase 2 946414-94-4
16
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
17
Daratumumab Approved Phase 1, Phase 2 945721-28-8
18
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
19
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
20
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
21
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
22
Oblimersen Experimental, Investigational Phase 2 190977-41-4
23
Mitoguazone Investigational Phase 2 459-86-9
24
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
25 Protein Kinase Inhibitors Phase 2
26 Imatinib Mesylate Phase 2 220127-57-1 123596
27 Folic Acid Antagonists Phase 2
28 Interleukin-12 Phase 2
29 topoisomerase I inhibitors Phase 2
30 Angiopeptin Phase 2
31 Poly ICLC Phase 1, Phase 2
32 Mitogens Phase 2
33 Endothelial Growth Factors Phase 2
34 Antibodies, Blocking Phase 2
35 Etoposide phosphate Phase 2
36 glucocorticoids Phase 1, Phase 2
37 interferons Phase 1, Phase 2
38 Anti-Infective Agents Phase 1, Phase 2
39 Interferon-beta Phase 1, Phase 2
40 Anti-HIV Agents Phase 1, Phase 2
41 Analgesics, Non-Narcotic Phase 1, Phase 2
42 Antiviral Agents Phase 1, Phase 2
43 Analgesics Phase 1, Phase 2
44 Interleukin-2 Phase 1, Phase 2
45 Anti-Retroviral Agents Phase 1, Phase 2
46
Serine Investigational, Nutraceutical Phase 1, Phase 2 56-45-1 5951
47
Pasireotide Approved Phase 1 396091-73-9 9941444
48
Vinorelbine Approved, Investigational Phase 1 71486-22-1 60780 44424639
49
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
50
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
51
Everolimus Approved Phase 1 159351-69-6 70789204 6442177
52
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
53
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
54
Prednisone Approved, Vet_approved Phase 1 53-03-2 5865
55
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
56
Venetoclax Approved, Investigational Phase 1 1257044-40-8 49846579
57
Octreotide Approved, Investigational Phase 1 83150-76-9 383414 6400441
58
Tyrosine Approved, Investigational, Nutraceutical Phase 1 60-18-4 6057
59 Lorvotuzumab mertansine Investigational Phase 1 1008106-64-6
60
Vatalanib Investigational Phase 1 212141-54-3 151194
61 Molgramostim Investigational Phase 1 99283-10-0
62
Cortisone Experimental Phase 1 53-06-5 222786
63 Pancreatic Polypeptide Investigational Phase 1 59763-91-6
64 Antifungal Agents Phase 1
65 Gastrointestinal Agents Phase 1
66 Adjuvants, Immunologic Phase 1
67 Hormone Antagonists Phase 1
68 Liver Extracts Phase 1
69 Antineoplastic Agents, Hormonal Phase 1
70 Calcineurin Inhibitors Phase 1
71 Anti-Inflammatory Agents Phase 1
72 Immunoglobulins, Intravenous Phase 1
73 Immunoglobulin G Phase 1
74
Coal tar Approved 8007-45-2
75 Dermatologic Agents
76 Fluorodeoxyglucose F18
77 Edotreotide
78 Radiopharmaceuticals

Interventional clinical trials:

(showing 98, show less)
# Name Status NCT ID Phase Drugs
1 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
2 STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial Recruiting NCT03712605 Phase 3
3 A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Clinically Detected Lymph Node Metastases Recruiting NCT03271372 Phase 3 Avelumab
4 A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913) Recruiting NCT03783078 Phase 3 Pembrolizumab (MK-3475)
5 A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00068783 Phase 2 imatinib mesylate
6 A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
7 A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
8 A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma Completed NCT01440816 Phase 2
9 A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
10 Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II. Completed NCT02351128 Phase 2 Lanreotide
11 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Completed NCT03241173 Phase 1, Phase 2 INCAGN01949;Nivolumab;Ipilimumab;INCAGN01949
12 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201) Recruiting NCT03599713 Phase 2 Retifanlimab
13 A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2 TALIMOGENE LAHERPAREPVEC (TVEC)
14 A Phase 2, Open-Label, Study of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy Recruiting NCT03787602 Phase 2 KRT-232
15 A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma Recruiting NCT03071406 Phase 2 Nivolumab;Ipilimumab
16 A Phase II Study of Palliative Radiation Therapy and Anti-PD-1/PD-L1 Checkpoint Blockade in Patients With Metastatic Merkel Cell Carcinoma Recruiting NCT03988647 Phase 2 Pembrolizumab
17 QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor. Recruiting NCT03853317 Phase 2
18 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
19 A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab
20 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
21 A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers Recruiting NCT03901573 Phase 1, Phase 2 NT-I7;atezolizumab
22 A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab or Cemiplimab in Patients With Advanced Solid Tumors Recruiting NCT03684785 Phase 1, Phase 2 AST-008
23 Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MCPyV-Specific TCRs Combined With Avelumab and Class I MHC-Upregulation in Patients With Metastatic MCC Refractory to PD-1 Axis Blockade Recruiting NCT03747484 Phase 1, Phase 2 Avelumab
24 Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation Recruiting NCT02196961 Phase 2 Nivolumab
25 QUILT-3.055: A Phase IIb, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment With PD-1/PD-L1 Checkpoint Inhibitor Therapy Recruiting NCT03228667 Phase 2 ALT-803 + Pembrolizumab;ALT-803 + Nivolumab;ALT-803 + Atezolizumab;ALT-803 + Avelumab
26 A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and in Combination With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting NCT03435640 Phase 1, Phase 2 NKTR-262;bempegaldesleukin;nivolumab
27 Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection Recruiting NCT02479698 Phase 2
28 Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized Clinical Phase II Trial Recruiting NCT03040180 Phase 2 Electrochemotherapy with bleomycin
29 A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers Recruiting NCT03935893 Phase 2 Fludarabine + Cyclophosphamide combination
30 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2 INCAGN01876;Nivolumab;Ipilimumab
31 A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy Recruiting NCT03544723 Phase 2 Ad-p53
32 UCDCC#271: A Phase I/II Trial of Epacadostat (Indolamine 2,3 Dioxygenase Inhibitor), Intralesional SD101 (Toll-receptor 9 Agonist), and Radiotherapy in Patients With Advanced Solid Tumors and Lymphoma Recruiting NCT03322384 Phase 1, Phase 2 epacadostat;SD-101
33 Avelumab (Bavencio) With IL-15 in Subjects With Clear-cell Renal Carcinoma Recruiting NCT04150562 Phase 2 rhIL-15
34 A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin Active, not recruiting NCT01013779 Phase 2 Carboplatin;Etoposide
35 A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma Active, not recruiting NCT02155647 Phase 2 Avelumab
36 A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC) Active, not recruiting NCT02267603 Phase 2
37 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02514824 Phase 1, Phase 2 MLN0128
38 A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma Active, not recruiting NCT03304639 Phase 2
39 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02036476 Phase 2 Cabozantinib
40 Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC) Active, not recruiting NCT02465957 Phase 2
41 Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab Active, not recruiting NCT02584829 Phase 1, Phase 2 Avelumab
42 A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Active, not recruiting NCT03277352 Phase 1, Phase 2 INCAGN01876;Epacadostat;Pembrolizumab
43 Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors Active, not recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
44 A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy Not yet recruiting NCT04393753 Phase 2 domatinostat in combination with avelumab
45 A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma Not yet recruiting NCT04291885 Phase 2 Avelumab;Placebo
46 A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers Not yet recruiting NCT04260802 Phase 1, Phase 2 OC-001;OC-001 in Combination
47 A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma Not yet recruiting NCT04261855 Phase 1, Phase 2 Avelumab
48 Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma - KAPVEC Not yet recruiting NCT04065152 Phase 2 Talimogene laherparepvec
49 Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Terminated NCT01758458 Phase 1, Phase 2
50 Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma Terminated NCT02054884 Phase 2 Arm A: F16IL2 in combination with paclitaxel;Arm B: Paclitaxel
51 Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin's Lymphoma Terminated NCT02501473 Phase 1, Phase 2 G100;Pembrolizumab;Rituximab
52 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
53 NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy Withdrawn NCT03167164 Phase 1, Phase 2 Capecitabine;Cisplatin;Cyclophosphamide;5-fluorouracil;Leucovorin;nab-Paclitaxel;omega-3-acid ethyl esters
54 Phase II Open-Label Trial of Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
55 A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma Completed NCT02035657 Phase 1
56 A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma Completed NCT01652547 Phase 1 Pasireotide sub-cutaneous formulation;Pasireotide lon acting release formulation
57 A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901 Completed NCT00346385 Phase 1 BB-10901
58 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
59 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
60 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
61 Treatment of Inoperable Colorectal Cancer With Electrochemotherapy Through an Endoscopic System Completed NCT01172860 Phase 1
62 A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies Recruiting NCT03538028 Phase 1
63 Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell Carcinoma Recruiting NCT03798639 Phase 1
64 A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer Recruiting NCT03458117 Phase 1
65 A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies Recruiting NCT03652077 Phase 1 INCAGN02390
66 A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors Recruiting NCT04234113 Phase 1 SO-C101;pembrolizumab
67 Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors Recruiting NCT04116320 Phase 1 Imiquimod;Standard of Care PD-1 Therapy
68 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) Recruiting NCT03841110 Phase 1 FT500;Nivolumab;Pembrolizumab;Atezolizumab;Cyclophosphamide;Fludarabine
69 A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting NCT03629756 Phase 1 AB928;AB122
70 A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Recruiting NCT03589339 Phase 1 NBTXR3
71 Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Recruiting NCT04160065 Phase 1
72 Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Recruiting NCT03816332 Phase 1 Prednisone;Tacrolimus
73 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers Recruiting NCT03212404 Phase 1 CK-301 (cosibelimab)
74 Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH) Recruiting NCT04187872 Phase 1
75 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors Recruiting NCT03000257 Phase 1 Venetoclax;Rovalpituzumab Tesirine;ABBV-181
76 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03071757 Phase 1 ABBV-368;ABBV-181
77 AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma - a Randomized, Open Label, 3 Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1R132H-specific Peptide Vaccine in Combination With Checkpoint Inhibitor Avelumab Recruiting NCT03893903 Phase 1 IDH1R132H peptide vaccine;Avelumab
78 A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies. Recruiting NCT03905135 Phase 1 rhIL-15
79 A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors Not yet recruiting NCT04242199 Phase 1 INCB099280
80 A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors Not yet recruiting NCT04272034 Phase 1 INCB099318
81 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
82 A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides Terminated NCT02890368 Phase 1 TTI-621 Monotherapy;TTI-621 + PD-1/PD-L1 Inhibitor;TTI-621 + pegylated interferon-α2a
83 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
84 Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC) Approved for marketing NCT03089658 Avelumab
85 Optical Biopsy of Human Skin in Conjunction With Laser Treatment Completed NCT00540566
86 The Impact of Total Body Skin Examination on Skin Cancer Detection Completed NCT00765193
87 Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures Completed NCT01526486
88 Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy (PRURICHECKPOINT) Completed NCT04365244
89 Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin Completed NCT02704039
90 Immunotherapy Multi-omics Specimen Protocol A Recruiting NCT03370861
91 French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas Recruiting NCT03210935
92 Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Recruiting NCT04106167
93 A Diagnostic Sensitivity Study Comparing Intradermal ICG and NIRFI With Intradermal Technetium 99m and Traditional Lymphoscintigraphy for Transcutaneous Identification of Sentinel Lymph Nodes in Malignant Melanoma Recruiting NCT03545334
94 Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol Recruiting NCT02471352
95 Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients Recruiting NCT03583528
96 Clinical Implementation of a Novel Ultrasound Technology for the Evaluation of Skin Lesions and Sentinel Lymph Node Recruiting NCT03914846
97 Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable Recruiting NCT01920516 Melphalan
98 Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases Withdrawn NCT02507076 isolated limb perfusion;melphalan

Search NIH Clinical Center for Merkel Cell Carcinoma

Genetic Tests for Merkel Cell Carcinoma

Anatomical Context for Merkel Cell Carcinoma

MalaCards organs/tissues related to Merkel Cell Carcinoma:

40
Skin, Lymph Node, T Cells, Brain, Liver, Lung, Pancreas

Publications for Merkel Cell Carcinoma

Articles related to Merkel Cell Carcinoma:

(showing 2898, show less)
# Title Authors PMID Year
1
Merkel cell carcinoma: lack of KIT positivity and implications for the use of imatinib mesylate. 54 61
19276970 2009
2
Metastatic Merkel cell carcinoma with positive expression of thyroid transcription factor-1--a case report. 61 54
19461245 2009
3
A malignant cutaneous neuroendocrine tumor with features of Merkel cell carcinoma and differentiating neuroblastoma. 61 54
19318809 2009
4
Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. 54 61
18813128 2009
5
Merkel cell carcinoma within follicular cysts: report of two cases. 61 54
18988316 2008
6
MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. 54 61
18587322 2008
7
Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. 54 61
18408656 2008
8
Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis. 61 54
18084259 2008
9
TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. 54 61
17885674 2007
10
RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO. 61 54
17958888 2007
11
Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. 61 54
17476292 2007
12
Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. 61 54
17695419 2007
13
Merkel cell carcinoma metastasizing to the kidney mimicking primary neuroendocrine renal cancer. 61 54
17550389 2007
14
Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. 61 54
17381803 2007
15
Merkel cell tumor in a trichilemmal cyst: collision or association? 61 54
17414443 2007
16
Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. 54 61
16498399 2006
17
Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. 54 61
16625069 2006
18
Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. 61 54
16538063 2006
19
Tenascin-C expression in Merkel cell carcinoma lymph node metastasis. 61 54
16499659 2006
20
CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both? 54 61
16115052 2005
21
Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. 61 54
16027284 2005
22
B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas. 61 54
15832095 2005
23
Tenascin-C in primary Merkel cell carcinoma. 54 61
15735164 2005
24
KIT receptor (CD117) expression in Merkel cell carcinoma. 61 54
14996126 2004
25
Expression of adhesion molecules and cytokeratin 20 in merkel cell carcinomas. 54 61
15299198 2004
26
[Merkel cell carcinoma. Clinical and histological differential diagnosis, diagnostic approach and therapy]. 61 54
14634746 2003
27
Expression of MUC 1 and Ep-CAM in Merkel cell carcinomas: implications for immunotherapy. 54 61
12844224 2003
28
Somatostatin analogue scintigraphy in Merkel cell tumours. 54 61
12828740 2003
29
Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. 61 54
12605092 2003
30
Merkel cell carcinoma composed of small, intermediate and squamous cell foci showing mutually exclusive expression of neuroendocrine markers and cytokeratin 20. 61 54
12534628 2003
31
Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. 61 54
14586067 2003
32
CD117 (KIT receptor) expression in Merkel cell carcinoma. 54 61
12142606 2002
33
Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. 61 54
12004304 2002
34
Primary undifferentiated small cell carcinoma (Merkel cell carcinoma) in a patient after heart transplantation--case report. 54 61
12476622 2002
35
Merkel cell carcinoma of the parotid gland associated with Warthin tumour: report of two cases. 54 61
11683932 2001
36
Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. 61 54
11533085 2001
37
[Merkel cell carcinoma: a diagnostic and therapeutic challenge]. 54 61
11357530 2001
38
Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. 61 54
11175640 2001
39
Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. 61 54
10976695 2000
40
Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. 54 61
10728812 2000
41
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. 54 61
10757334 2000
42
Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. 54 61
10027519 1999
43
Mixed Merkel cell carcinoma and squamous cell carcinoma of the skin. 54 61
9810922 1998
44
Pagetoid Merkel cell carcinoma: epidermal origin of the tumor. 61 54
9870679 1998
45
Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. 54 61
9042291 1997
46
Aberrant FHIT transcripts in Merkel cell carcinoma. 61 54
8653678 1996
47
Cutaneous lymphoma-simulating Merkel cell carcinoma-molecular genetic demonstration of a clonal disease with divergent immunophenotypes. 61 54
8539236 1995
48
[Detection of somatostatin receptors in tumors in the area of the head and neck and their clinical importance]. 54 61
7908199 1994
49
Immunohistochemical and immunoelectron microscopic demonstration of chromogranin A in formalin-fixed tissue of Merkel cell carcinoma. 61 54
8432919 1993
50
An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report. 61
32006066 2020
51
[Merkel cell carcinoma in chronic lymphocytic leukemia : Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil]. 61
32394077 2020
52
Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. 61
32219902 2020
53
Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. 61
32573984 2020
54
p110δ PI3K as a therapeutic target of solid tumours. 61
32556179 2020
55
[Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors]. 61